Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

March 12, 2021

Study Completion Date

December 31, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

Olaparib

Tablet, 100mg and 150mg

DRUG

Cediranib

Tablet 15mg and 20mg

DRUG

Paclitaxel

Intravenous (IV)

Trial Locations (14)

BT9 7AM

Belfast City Hospital, Belfast

Unknown

Mount Vernon Cancer Centre, Northwood

Royal United Hospital, Bath

Velindre, Cardiff

Beatson West of Scotland Cancer Centre, Glasgow

Clatterbridge Cancer Centre, Liverpool

Royal Marsden Chelsea & Sutton, London

University College London, London

The Christie, Manchester

NG5 1PB

City Hospital Nottingham, Nottingham

GU2 7XX

Royal Surrey County Hospital, Guildford

EC1A 7BE

St Bartholomew's, London

W12 0HS

Hammersmith Hospital, London

OX3 7LE

Churchill Hospital, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Oxford

OTHER